Exploring Thiazolidine-2,4‑dione derivatives as privileged scaffolds for targeted anticancer agents: Biological activity and structure-activity relationship (SAR) insights
Mayavan Viji, Md Ashadul Sk, Gurubasavaraja Swamy Purawarga Matada(Drug Discovery Laboratory (Norway)), Rohit Pal(Unknown), Pronoy Kanti Das(Drug Discovery Laboratory (Norway)), E Haripriya, S. Mounika, B V Manjushree, Abhishek Ghara(Unknown)
Cited by 7
Related Papers
Molecular docking and molecular dynamic studies: screening of phytochemicals against EGFR, HER2, estrogen and NF-KB receptors for their potential use in breast cancer
|Journal of Biomolecular Structure and Dynamics|2021|37
DDR1 and DDR2: a review on signaling pathway and small molecule inhibitors as an anticancer agent
|Medicinal Chemistry Research|2021|35
Benzothiazole a privileged scaffold for Cutting-Edges anticancer agents: Exploring drug design, structure-activity relationship, and docking studies
|European Journal of Medicinal Chemistry|2024|32
An assessment of EGFR and HER2 inhibitors with structure activity relationship of fused pyrimidine derivatives for breast cancer: a brief review
|Journal of Biomolecular Structure and Dynamics|2023|28
An updated literature on BRAF inhibitors (2018–2023)
|Molecular Diversity|2023|24